The pitch is your brand. The picture is the problem.
White-label GLP-1 is sold in one sentence. OpenLoop's program page puts it as a question and an answer: "Can I offer GLP-1s under my own brand? Yes. With OpenLoop, the clinical GLP-1 program runs under your brand." Other vendors say the same thing in their own words. The clinicians, the pharmacy and the software are theirs. The name on the front is yours.
That is a fair description of the program. It stops being fair at the product shoot. The founder puts the logo on the product page, and then on the vial in the photograph, because that is what a brand does. The FDA reads that photograph differently. Under its labeling rule, a name on a drug label with nothing next to it says the named company made the drug. In June 2026 the agency wrote to a telehealth company about exactly that picture.
Our Standard 8 post covers the words on the page. This one is about the name on the label: the rule, what the letter cited, what a qualifier is, and what to settle with the pharmacy before anyone photographs a vial.
What does the FDA say a name on a drug label means?
The rule is 21 CFR 201.1, titled "Drugs; name and place of business of manufacturer, packer, or distributor." Paragraph (h) is the part that reaches a brand. It reads, in full:
"(1) Except as provided in this section, no person other than the manufacturer, packer, or distributor may be identified on the label of a drug or drug product."
"(2) The appearance on a drug product label of a person's name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section."
"(3) If the names of two or more persons appear on the label of a drug or drug product, the label may identify which of the persons is to be contacted for further information about the product."
"(4) If a trademark appears on the drug or drug product label or appears as a mark directly on the drug product (e.g., tablet or capsule), the label may identify the holder or licensee of the trademark. The label may also state whether the person identified holds the trademark or is licensee of the trademark."
"(5) If the distributor is named on the label, the name shall be qualified by one of the following phrases: 'Manufactured for ______', 'Distributed by ______', 'Manufactured by ______ for ______', 'Manufactured for _____by _____', 'Distributor: ______', 'Marketed by ______'. The qualifying phrases may be abbreviated."
"(6) If the packer is identified on the label, the name shall be qualified by the phrase 'Packed by ______' or 'Packaged by ______'. The qualifying phrases may be abbreviated."
Paragraph (l) closes the loop: "A drug product is misbranded under section 502(a) of the act if its labeling identifies a person as manufacturer, packer, or distributor, and that identification does not meet the requirements of this section."
The list of who may appear on the label is short: manufacturer, packer, distributor, and nobody else unless the section itself says so, as paragraph (h)(4) does for the holder or licensee of a trademark. A name with nothing next to it is not neutral; the rule assigns it a meaning, sole manufacturer. The rule's "manufacturer" is defined in paragraph (b) as the person who performs all of the operations required to produce the product, from mixing to filling sterile drugs into dispensing containers. For a compounded GLP-1 that is the pharmacy or the outsourcing facility, not the company whose logo is on the storefront.
Does the rule apply to a prescription dispensed to one patient?
This is the question the pharmacy will raise, and the answer is in two places.
Paragraph (a) of 201.1, the duty to name the manufacturer, packer or distributor at all, ends with: "This paragraph does not apply to any drug or drug product dispensed in accordance with section 503(b)(1) of the act." A pharmacy filling a prescription has no duty under 201.1 to say who made the drug.
The FDA addressed what happens when a name appears anyway, in the preamble to the rule published in the Federal Register on 15 April 1980. At 45 FR 25765 it says there is no affirmative obligation on pharmacists to identify the manufacturer, packer or distributor on dispensing containers, and then: "However, this does not mean that if a pharmacist voluntarily makes a representation on a drug or drug product label as to the manufacturer, packer, or distributor that the other sections of the regulation would not apply. To the contrary, if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1 of the regulations regarding the designation of the manufacturer, packer, or distributor."
The silence is permitted. The name, once it appears, is not.
The statute the pharmacy dispenses under, section 503(b)(2) of the Federal Food, Drug, and Cosmetic Act, says what a dispensed prescription's label must carry to earn its exemption from most labeling rules: "the name and address of the dispenser, the serial number and date of the prescription or of its filling, the name of the prescriber, and, if stated in the prescription, the name of the patient, and the directions for use and cautionary statements, if any, contained in such prescription." The exemption excludes section 502(a), so a false or misleading label is still a misbranding on a dispensed prescription. The same subsection says the exemption does not apply to a drug dispensed "in the course of the conduct of a business of dispensing drugs pursuant to diagnosis by mail", which is a question for your counsel and not for this post. If the drug comes from a 503B outsourcing facility, section 503B(a)(10)(A) lists, as a condition of the 503B exemption, a label that includes "the statement 'This is a compounded drug.'" and "the name, address, and phone number of the applicable outsourcing facility". Neither list has a line for the telehealth brand.
What did the FDA actually cite?
On 3 March 2026 the FDA announced 30 warning letters to telehealth companies over compounded GLP-1 claims on their websites. The announcement says the primary violations included two things: "making claims implying sameness with FDA-approved products and obscuring product sourcing by advertising drug products branded with the telehealth firm's name or trademark without qualification, implying they are the compounder." The second half is this post. "Without qualification" is the rule's own phrase.
The letter that shows it in practice is dated 8 June 2026, to Medica Weight Loss, reference MARCS-CMS 728284, following a review of the company's website in March 2026. Its first numbered violation reads: "The compounded semaglutide and tirzepatide products displayed on your website identify 'medica weight loss' on the pictured label, suggesting Medica Weight Loss is the compounder of those drugs when in fact it is not."
The footnote to that sentence is the legal chain. It quotes 201.1(h)(2) in full, then adds "see also FD&C Act § 503(b)" and "FD&C Act § 503B(a)(10)(A)(ii)". It acknowledges that 201.1(a) does not apply to drugs dispensed under 503(b)(1), and answers with the 1980 preamble passage quoted above. Then it adds the sentence that matters most for a pharmacy partner: the labels "as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&C Act", and "nor do they appear to comply with the requirements of section 503(b)(2)".
The FDA did not inspect a vial. It read a product image on a website, treated the pictured label as the label, and found a name on it that belonged to a company that did not compound the drug. The letter cites sections 502(a) and 502(bb) of the Act and gives fifteen business days to respond. The second step it lists for that response is "Providing a representative sample of labeling for such drug products".
For balance: another letter of the same date, to Altru Telehealth, reference 728274, cites website copy only and has no label item. The label citation is not in every letter. It is in the one whose product photographs carried the brand.
What is a qualifier, and can you use one?
A qualifier is one of the phrases in 201.1(h)(5). It sits next to the name and says what the named company's role is. "Manufactured for Acme Health by Example Pharmacy" is a qualified name. "Acme Health" on its own is not.
Whether your company can use one at all is the question this post will not answer, because the rule does not answer it for you. Paragraph (h)(1) limits the label to the manufacturer, the packer and the distributor. A telehealth brand that neither compounds, packs nor ships the drug may be a distributor in the rule's sense, in which case it can appear with a qualifier, or it may be none of the three, in which case (h)(1) says it does not appear. Paragraph (h)(4) adds a third path for a trademark on the label, whose holder or licensee the label "may identify". The rule was written in 1980 for drug companies and contract manufacturers. Where a telehealth brand falls is a question for the pharmacy that prints the label and for your counsel, and it should be settled in writing before the first vial is photographed.
Two things are not open. Compounded drugs are not FDA approved, which the FDA's March announcement states in a sentence of its own. And a name with no qualifier is a sole-manufacturer claim whatever the company's role turns out to be.
Where does LegitScript come in?
LegitScript has no label rule. Its nine Healthcare Certification standards do not mention drug labels or product images, and its GLP-1 guidance page, which lists what it considers violative content, says nothing about branding. Do not look for one.
What it has is Standard 8, Transparency, which requires that "all practices and offers are accurate, transparent, and not misleading to patients or the public, including but not limited to any material detail regarding the pharmacy, pharmacy staff, medical practitioners, drugs, treatments, or financial transactions", and names the FTC and FDA as examples of the bodies whose support a benefit claim needs. Its application checklist says, under Patient Services: "Please ensure advertising claims are in line with current guidelines. For US merchants, this includes guidelines from the FDA and FTC." A product image the FDA has called false and misleading in a public warning letter is hard to square with that line.
There is a second seam. The name the label obscures is the same name Standard 4 makes you disclose: it says partners "essential to supporting the applicant's continuum of care, such as partner pharmacies responsible for the fulfillment of prescription medication to patients" are generally required to be LegitScript certified or accredited by another recognised body, with exceptions only at its discretion, and our partner pharmacy post covers that disclosure. A storefront that tells LegitScript who the pharmacy is, and tells the patient through the vial that the brand made the drug, is telling two reviewers two different stories about the same fact.
What to settle with the pharmacy before the product shoot
- Who compounds the drug, by legal name. A 503A pharmacy or a 503B outsourcing facility, and which. Our 503A and 503B explainer covers the difference. Standard 4 needs this name and so does the label.
- What the real dispensed label says. Ask for a representative label, the same thing the FDA asks for in its letters. If it carries the pharmacy's name and the 503(b)(2) items, that is the label.
- Whether your name appears on it, and how. If the pharmacy puts your name on the label, ask which paragraph of 201.1(h) it is relying on and which qualifier it prints, in writing. If its position is that your company is not a manufacturer, packer or distributor, your name does not go on the label.
- Whether the photograph matches the label. A mock-up vial with your logo and nothing else is the image the Medica letter describes. A photograph of the real labeled product, or one with no legible label, is not.
- Where the brand lives. The program name, the storefront, the intake, the patient portal, the emails and the cold chain handoff are yours to brand. The drug label is governed by a rule that was not written with you in mind.
For the product page itself, the three cases are: the compounder's name on the pictured label, your name with a qualifier the rule allows if your company is a person 201.1 lets on the label, or no label in the image. "Your logo on the vial" is not a fourth case.
The FDA decides what is misbranded, LegitScript decides certification in its own discretion, and nothing here predicts either decision on your business; this is website and product page guidance, not legal, regulatory or medical advice. ToolBX Media is a LegitScript partner, and the product images are on the list when we read a compounded GLP-1 storefront before a submission, next to the copy. Score your own site with the LegitScript readiness score, work through the web developer's checklist, or have us read the storefront and the application together in a telehealth program fit review.
Common questions
Can I put my clinic's name on a compounded GLP-1 vial?
Not without a qualifier, and possibly not at all. Under 21 CFR 201.1(h)(1), no person other than the manufacturer, packer or distributor may be identified on the label of a drug product. Under 201.1(h)(2), a person's name on a drug label without qualification is a representation that the named person is the sole manufacturer, and if that is false the drug is misbranded under section 502(a) of the Federal Food, Drug, and Cosmetic Act. A distributor may appear only with one of the phrases in 201.1(h)(5), such as Manufactured for or Distributed by. Whether a telehealth company that neither compounds, packs nor ships the drug is a distributor who can appear with a qualifier, or a person who cannot appear on the label at all, is a question for the pharmacy and your counsel. The FDA cited a telehealth company for its own name on the pictured label in a warning letter dated 8 June 2026.
What does 'without qualification' mean on a drug label?
It means a name standing alone, with no phrase saying what the named company did. 21 CFR 201.1(h)(2) says the appearance on a drug product label of a person's name without qualification is a representation that the named person is the sole manufacturer of the product. The qualifiers the rule accepts for a distributor are listed in 201.1(h)(5): Manufactured for, Distributed by, Manufactured by (one) for (another), Manufactured for (one) by (another), Distributor:, and Marketed by. A packer gets Packed by or Packaged by under 201.1(h)(6). The FDA's 3 March 2026 announcement described the violation as advertising drug products branded with the telehealth firm's name or trademark without qualification, implying they are the compounder.
Does 21 CFR 201.1 apply to a prescription the pharmacy dispensed to one patient?
Paragraph (a) of 201.1, the duty to name the manufacturer, packer or distributor at all, does not apply to a drug dispensed in accordance with section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act. The rest of the section still does once a name appears. The FDA's preamble to the rule, at 45 FR 25765 on 15 April 1980, says there is no affirmative obligation on pharmacists to identify the manufacturer, packer or distributor on dispensing containers, but that if the label of a prescription drug product dispensed by a pharmacist does contain such a representation, it must comply with all the provisions of 201.1. The FDA quoted that passage in its June 2026 warning letter about a telehealth company's name on the pictured label.
Which FDA warning letter cited a telehealth brand's name on the vial?
The letter to Medica Weight Loss, reference MARCS-CMS 728284, dated 8 June 2026, following a review of the company's website in March 2026. Its first numbered violation says the compounded semaglutide and tirzepatide products displayed on the website identify the company's name on the pictured label, suggesting the company is the compounder of those drugs when in fact it is not. The footnote cites 21 CFR 201.1(h)(2), FD&C Act section 503(b) and section 503B(a)(10)(A)(ii), and the 1980 Federal Register preamble. It adds that the labels as depicted on the website do not indicate that the drugs are dispensed under section 503(b)(1), nor do they appear to comply with section 503(b)(2). Another letter of the same date, to Altru Telehealth, reference 728274, cites website copy only and has no label item. The FDA's 3 March 2026 announcement of 30 letters named the unqualified brand name as one of the primary violations.
What has to be on the label of a compounded GLP-1 the patient receives?
It depends on who compounded it. For a prescription dispensed by a pharmacy, section 503(b)(2) of the Federal Food, Drug, and Cosmetic Act exempts the drug from most labeling requirements if the label carries the name and address of the dispenser, the serial number and date of the prescription or of its filling, the name of the prescriber, the patient's name if the prescription states it, and the directions for use and cautionary statements in the prescription. The exemption does not remove section 502(a), which still makes a false or misleading label a misbranding. For a drug from a 503B outsourcing facility, section 503B(a)(10)(A) lists, as a condition of the 503B exemption, a label that includes the statement This is a compounded drug, the name, address and phone number of the outsourcing facility, and the lot number, established name, strength, compounding date, expiration date and other items the section lists. Neither list has a line for the telehealth brand.
Will LegitScript fail my site over a product image?
LegitScript's published standards do not mention drug labels or product images, and its GLP-1 guidance page lists violative content without a line on branding. What its Standard 8 does say is that all practices and offers must be accurate, transparent and not misleading regarding any material detail about the pharmacy, drugs or treatments, and that a benefit claim needs the support of a regulatory body such as the FTC or FDA. Its application checklist tells US merchants to ensure advertising claims are in line with guidelines from the FDA and FTC. An image the FDA has called false and misleading in a public letter is a hard thing to defend under that standard, and the sourcing it obscures is the same partner pharmacy Standard 4 requires you to disclose. LegitScript decides certification in its own discretion, so nobody can promise an outcome either way.
Sources
- eCFR, 21 CFR 201.1, Drugs; name and place of business of manufacturer, packer, or distributor, full text including paragraphs (a), (b), (h) and (l) checked 2026-11-12
- 21 U.S.C. 353(b), FD&C Act section 503(b), prescription dispensing and the label contents in (b)(2), 2024 edition at govinfo checked 2026-11-12
- 21 U.S.C. 353b(a)(10), FD&C Act section 503B, labeling of drugs compounded by an outsourcing facility, 2024 edition at govinfo checked 2026-11-12
- Federal Register, Vol. 45, No. 74, 15 April 1980, Drug Product Labels, final rule and preamble, 45 FR 25760 at 25765 and 25768 checked 2026-11-12
- U.S. FDA, press announcement, FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s, 3 March 2026 checked 2026-11-12
- U.S. FDA, warning letter MARCS-CMS 728284 to Medica Weight Loss, 8 June 2026, violation 1 and footnote 2 checked 2026-11-12
- U.S. FDA, warning letter MARCS-CMS 728274 to Altru Telehealth, 8 June 2026 checked 2026-11-12
- LegitScript, Healthcare Certification, the nine certification standards, Standard 4 and Standard 8 checked 2026-11-12
- LegitScript, Healthcare Certification Application Checklist, document CHM-CE202-CHE-03, Patient Services and Affiliates sections checked 2026-11-12
- LegitScript, GLP-1 Sales Online, What You Need to Know, the list of violative content checked 2026-11-12
- OpenLoop Health, White-label GLP-1 Virtual Care Program, frequently asked questions checked 2026-11-12
Want this costed for your build?
Tell us what you already have and what is not working, and we will come back with the shape of the work and what drives the number.